Home › Research › Prevention trials
Alzheimer's disease genetic risk score and neuroimaging in the FINGER lifestyle trial
Gazi Saadmaan, Maria Carolina Dalmasso, Alfredo Ramirez, Mikko Hiltunen, Nina Kemppainen, Jenni Lehtisalo, Francesca Mangialasche, Tiia Ngandu et al.. Alzheimer's & dementia : the journal of the Alzheimer's Association, 2024-04-22
Topic: Genetics and APOE
Plain-language summary
The APOE4 allele, but not AD-GRS, was associated with baseline lower hippocampus volume (β = -0.27, p = 0.001), greater amyloid deposition (β = 0.48, p = 0.001), 2-year decline in hippocampus (β = -0.27, p = 0.01), total gray matter volume (β = -0.25, p = 0.01), and cortical thickness (β = -0.28, p = 0.003). In analyses stratified by AD-GRS (below vs above median), the PiB composite score increased less in intervention versus control in the higher AD-GRS group (β = -0.60, p = 0.03). AD-GRS and APOE4 may have different impacts on potential intervention effects on amyloid, that is, less accumulation in the higher-risk group (AD-GRS) versus lower-risk group (APOE). HIGHLIGHTS: First study of neuroimaging and AD genetics in a multidomain lifestyle intervention. Possible intervention effect on brain amyloid deposition may rely on genetic risk. AD-GRS and APOE4 allele may have different impacts on amyloid during intervention.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Saadmaan, G., Dalmasso, M. C., Ramirez, A., Hiltunen, M., Kemppainen, N., Lehtisalo, J., et al. (2024). Alzheimer's disease genetic risk score and neuroimaging in the FINGER lifestyle trial. Alzheimer's & dementia : the journal of the Alzheimer's Association. https://doi.org/10.1002/alz.13843
Vancouver
Saadmaan G, Dalmasso MC, Ramirez A, Hiltunen M, Kemppainen N, Lehtisalo J, et al. Alzheimer's disease genetic risk score and neuroimaging in the FINGER lifestyle trial. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2024. doi:10.1002/alz.13843. PMID: 38647197.
BibTeX
@article{saadmaan2024-38647197,
author = {Saadmaan, Gazi and Dalmasso, Maria Carolina and Ramirez, Alfredo and Hiltunen, Mikko and Kemppainen, Nina and Lehtisalo, Jenni and Mangialasche, Francesca and Ngandu, Tiia and others},
title = {{Alzheimer's disease genetic risk score and neuroimaging in the FINGER lifestyle trial}},
journal = {Alzheimer's \& dementia : the journal of the Alzheimer's Association},
year = {2024},
doi = {10.1002/alz.13843},
pmid = {38647197},
url = {https://doi.org/10.1002/alz.13843}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- The APOE4 allele, but not AD-GRS, was associated with baseline lower hippocampus volume (β = -0.27, p = 0.001), greater amyloid deposition (β = 0.48, p = 0.001), 2-year decline in hippocampus (β = -0.27, p = 0.01), total gray matter volume (β = -0.25, p = 0.01), and cortical thickness (β = -0.28, p = 0.003).
- In analyses stratified by AD-GRS (below vs above median), the PiB composite score increased less in intervention versus control in the higher AD-GRS group (β = -0.60, p = 0.03).
- AD-GRS and APOE4 may have different impacts on potential intervention effects on amyloid, that is, less accumulation in the higher-risk group (AD-GRS) versus lower-risk group (APOE).
- HIGHLIGHTS: First study of neuroimaging and AD genetics in a multidomain lifestyle intervention.
- Possible intervention effect on brain amyloid deposition may rely on genetic risk.
New to this subject? Start with our plain-English guide: Prevention →
Study details
- Participants126
- Evidence strengthHigh
How this study scored 84/100
Published in a leading specialty journal, and it is a randomized controlled trial. Scored zero for effect reported because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record, multicenter collaboration and free to read, so those were left out: it earned 47 of the 56 points we could judge it on, which is 84 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Alzheimer's & dementia : the journal of the Alzheimer's Association) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 11 / 12 | A randomized controlled trial (from PubMed type “Randomized Controlled Trial”) |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2024 — within 3 year(s) of the newest study here |
| Sample size | 2 / 4 | 126 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 1 / 2 | Randomized (as stated in the record) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 38647197) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 47 / 56 | Scored on 10 of 20 parts. We have no data for the rest, so they are left out: 47 of the 56 points we could judge it on is 84 out of 100. |
| Total | 84 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Prevention trials from nearby years
Also tagged “genetics”
346 studies in the library carry the topic tag “genetics”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 346 tagged studies.